Amphotericin B cochleates - BioDelivery Sciences
Alternative Names: BioNasal Amphotericin B; Bioral amphotericin B; Bioral Amphotericin B; Encochleated amphotericin B; SinuNaseLatest Information Update: 24 Mar 2022
At a glance
- Originator BioDelivery Sciences International
- Developer Accentia Biopharmaceuticals; BioDelivery Sciences International; Drugs for Neglected Diseases Initiative Foundation
- Class Antifungals; Antiprotozoals; Macrolides
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chagas disease; Leishmaniasis; Mycoses; Rhinosinusitis; Sinusitis
Most Recent Events
- 22 Mar 2022 BioDelivery Sciences International has been acquired by Collegium Pharmaceuticals
- 11 Sep 2013 Discontinued - Phase-I for Mycoses in USA (PO)
- 11 Sep 2013 Discontinued - Phase-III for Rhinosinusitis in USA (Intranasal)